Solcoseril (protein-free haemodialysate from calf blood) gel 4.15 mg/g. 20 g. tube

Description

Solcoseril (protein-free haemodialysate from calf blood) gel 4.15 mg/g. 20 g. tube

Composition

active ingredient: protein-free haemodialysate from calf blood;

1 g of gel contains deproteinized hemoderivate from the blood of calves (Bos Taurus), chemically and biologically standardized, in terms of dry matter 4.15 mg;

excipients: methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), sodium carboxymethylcellulose, calcium lactate, pentahydrate; propylene glycol, lactic acid and / or sodium hydroxide solution 27%, water for injection.

Dosage form

Gel.

Basic physical and chemical properties: colorless, homogeneous, transparent gel.

Pharmacological group

Means for the treatment of wounds and ulcers. Preparations that promote healing (scarring) of wounds.
Code ATX D03A X.

Pharmacological properties

Solcoseril is a deproteinized hemoderivative from calf blood, obtained by dialysis and ultrafiltration, containing a wide range of natural low molecular weight substances with a molecular weight of 5000 Da, and only some of them are described chemically and pharmacologically.

In in vitro tests, as well as during preclinical and clinical studies, it was found that Solcoseryl:

• supports aerobic metabolism and oxidative phosphorylation, therefore, contributes to the supply of high-energy phosphates to undernourished cells;
• increases (in vitro) the use of oxygen and the supply of glucose to tissues and cells suffering from hypoxia and metabolically depleted;
• improves the processes of repair and regeneration of damaged tissues and / or tissues limited in sufficient amounts of nutrients;
• prevents or reduces secondary degeneration and pathological changes in reversibly damaged cellular systems;
• accelerates collagen synthesis in in vitro models;
• stimulates cell proliferation and movement in vitro.

Thus, the drug protects tissues in a state of hypoxia and nutritional deficiency, promotes tissue regeneration, accelerates and improves wound healing.

Indications

Minor injuries, venous ulcers, burns of the 1st and 2nd degree of severity (for example, boiling water), frostbite.

Contraindications

Hypersensitivity to the active substance or any other component of the drug.

Use during pregnancy or lactation

When using the drug in animal experiments, there was no risk to the fetus, however, there are no clinical data on the use of the drug in women during pregnancy. Solcoseryl should be used with caution during pregnancy. There are no restrictions on the use of the drug during breastfeeding.

Dosage and administration

The drug Solcoseril gel is intended for external use.

The gel is recommended to be applied to wet wounds. Apply a thin layer to a cleansed wound twice a day. Solcoseryl gel is used in the initial phase of wound healing to activate the granulation process. After the formation of areas of epithelialization of the wound, it is recommended to lubricate with solcoseryl ointment.

Children

Experience with children is limited.

Overdose

No cases of overdose have been reported.

Side effects

In rare cases, allergic reactions are possible, in the event of which treatment should be discontinued.

After applying the gel, the patient may experience a burning sensation that does not require discontinuation of the drug.